This study is for adults with advanced extrapulmonary neuroendocrine cancer (epNEC), a type of cancer that starts outside the lungs. Researchers want to see if adding obrixtamig to standard chemotherapy (carboplatin and etoposide) helps people live longer compared to receiving standard chemotherapy alone. Obrixtamig is a molecule that might help your immune system fight cancer. The study also aims to test a device that measures a tumor marker called delta-like ligand 3 (DLL3). To join, you must have advanced epNEC that is poorly differentiated and has a high Ki-67 or mitotic rate. The study plans to enroll 390 participants. The main goal is to measure overall survival for up to 38 months.

Study design

This study will randomly assign participants into two groups, meaning by chance. One group will receive obrixtamig plus standard chemotherapy, and the other will receive standard chemotherapy alone.

What's involved

One group of participants will receive obrixtamig and standard chemotherapy, followed by obrixtamig alone for up to 3 years.

Compensation

Not stated in the trial record.

Follow-up

Overall survival will be measured for up to 38 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.